NATERA INC (NTRA)
US6323071042 - Common Stock
We assign a fundamental rating of 3 out of 10 to NTRA. NTRA was compared to 588 industry peers in the Biotechnology industry. While NTRA seems to be doing ok healthwise, there are quite some concerns on its profitability. NTRA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NTRA had negative earnings in the past year.
NTRA had a negative operating cash flow in the past year.
In the past 5 years NTRA always reported negative net income.
NTRA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
NTRA's Return On Assets of -30.15% is fine compared to the rest of the industry. NTRA outperforms 72.99% of its industry peers.
The Return On Equity of NTRA (-56.80%) is better than 63.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.15% | ||
| ROE | -56.8% | ||
| ROIC | N/A |
ROA(3y)-35.86%
ROA(5y)-30.73%
ROE(3y)-68.88%
ROE(5y)-59.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 45.52%, NTRA is doing good in the industry, outperforming 79.66% of the companies in the same industry.
NTRA's Gross Margin has improved in the last couple of years.
NTRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y5.07%
2. Health
2.1 Basic Checks
NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTRA has more shares outstanding than it did 1 year ago.
NTRA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NTRA has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 7.89 indicates that NTRA is not in any danger for bankruptcy at the moment.
NTRA's Altman-Z score of 7.89 is amongst the best of the industry. NTRA outperforms 84.10% of its industry peers.
A Debt/Equity ratio of 0.47 indicates that NTRA is not too dependend on debt financing.
The Debt to Equity ratio of NTRA (0.47) is worse than 72.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.89 |
ROIC/WACCN/A
WACC9.09%
2.3 Liquidity
A Current Ratio of 4.10 indicates that NTRA has no problem at all paying its short term obligations.
NTRA has a Current ratio (4.10) which is in line with its industry peers.
NTRA has a Quick Ratio of 3.96. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
NTRA's Quick ratio of 3.96 is in line compared to the rest of the industry. NTRA outperforms 45.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.1 | ||
| Quick Ratio | 3.96 |
3. Growth
3.1 Past
NTRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.96%, which is quite impressive.
Looking at the last year, NTRA shows a very strong growth in Revenue. The Revenue has grown by 31.99%.
The Revenue has been growing by 33.25% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)31.96%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q53.28%
Revenue 1Y (TTM)31.99%
Revenue growth 3Y40.42%
Revenue growth 5Y33.25%
Revenue growth Q2Q43.17%
3.2 Future
Based on estimates for the next years, NTRA will show a very strong growth in Earnings Per Share. The EPS will grow by 24.56% on average per year.
NTRA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.40% yearly.
EPS Next Y37.44%
EPS Next 2Y29.39%
EPS Next 3Y24.56%
EPS Next 5YN/A
Revenue Next Year26.81%
Revenue Next 2Y22.17%
Revenue Next 3Y19.92%
Revenue Next 5Y18.4%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NTRA. In the last year negative earnings were reported.
Also next year NTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NTRA's earnings are expected to grow with 24.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.39%
EPS Next 3Y24.56%
5. Dividend
5.1 Amount
NTRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NATERA INC
NASDAQ:NTRA (4/17/2024, 7:16:12 PM)
After market: 90.04 -0.29 (-0.32%)90.33
+0.01 (+0.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.91B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.15% | ||
| ROE | -56.8% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.52% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.1 | ||
| Quick Ratio | 3.96 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)31.96%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y37.44%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)31.99%
Revenue growth 3Y40.42%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y